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OBJECTIVE: The objective of this selective evidence-based medicine (EBM) review is to 
determine whether or not probiotics are effective in improving quality of life in adults with 
irritable bowel syndrome. 
 
STUDY DESIGN: A systematic review of three double-blind randomized controlled trials 
(RCTs) written in the English language, published between the years 2016 and 2018. 
 
DATA SOURCES: Three randomized controlled trials were published in peer-reviewed journals 
and found using PubMed and GoogleScholar databases. 
 
OUTCOME(S) MEASURED: All three of the included studies measured the quality of life in 
adults with irritable bowel syndrome (IBS) utilizing the self-reported IBS-QOL questionnaire.  
 
RESULTS: Each of the RCTs demonstrated an improvement in the quality of life in patients 
with IBS. One study (Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, Gaddam 
S. Benef Microbes. 2018;9(5):697-706. doi: 10.3920/BM2017.0105) found improvement in QOL 
at the conclusion of the trial at 12 weeks, but did not include a measure of precision. However, 
Mezzasalma et al. (Biomed Res Int. 2016;2016:4740907. doi: 10.1155/2016/4740907) and 
Ishaque et al. (BMC Gastroenterol. 2018;18(1):9. doi: 10.1186/s12876-018-0788-9) both showed 
a statistically significant (p < 0.001) increase in patients’ quality of life following the 
intervention versus placebo at the conclusion of the study on day 60 and at the follow-up visit at 
five months, respectively. However, Ishaque et al. (BMC Gastroenterol. 2018;18(1):9. doi: 
10.1186/s12876-018-0788-9) failed to have comparable baseline data between the two treatment 
arms.  
 
CONCLUSIONS: The three randomized-controlled trials provided varying degrees of evidence 
that probiotic supplementation can improve quality of life in patients who suffer from irritable 
bowel syndrome. Mezzasalma et al. (Biomed Res Int. 2016;2016:4740907. doi: 
10.1155/2016/4740907) provided sufficient data to support the efficacy in probiotic use and 
effect on IBS. However, the studies by Preston et al. (Benef Microbes. 2018;9(5):697-706. doi: 
10.3920/BM2017.0105) and Ishaque et al. (BMC Gastroenterol. 2018;18(1):9. doi: 
10.1186/s12876-018-0788-9) demonstrated similar outcomes but with less reliability. Further 
research is necessary in order to solidify the role that these probiotics can play in managing IBS.  
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INTRODUCTION 
 Irritable bowel syndrome (IBS) is a chronic, functional condition that causes alterations 
in the gastrointestinal (GI) tract which produce various discomforting symptoms, however no 
physical damage is evident. IBS can have many different presentations, including abdominal 
pain, bloating, and changes in stool frequency. They are classified as follows: constipation-
predominant (IBS-C), diarrhea-predominant (IBS-D), or mixed (IBS-M).1 This paper evaluates 
three randomized, double-blind, placebo-controlled trials comparing the efficacy of probiotic 
supplementation for improving quality of life in adults suffering from irritable bowel syndrome.  
IBS affects greater than 48 million Americans and has a worldwide prevalence of 10-
20% of adults.2 It is considered the most frequent diagnosis in gastroenterology practices and 
primary care offices.3 In the United States, approximately 2.4 to 3.5 million physician visits 
annually can be attributed to IBS patients.4 Because this disorder is common,  it is estimated that 
greater than $21 billion is spent annually on direct and indirect IBS-related costs.4  
 The absence of physical changes to the GI tract makes IBS difficult to definitively 
diagnose and thus, it is considered a diagnosis of exclusion. Based on the Rome III criteria, IBS 
can be diagnosed by the presence of symptoms for at least 6 months in addition to symptoms 
present at least three days per month in the last three months.3 The exact etiology of this 
condition is unknown; however, multiple risk factors have been identified, such as: stress, female 
sex, history of mental illness such as anxiety and/or depression, food intolerance, history of 
migraines, and chronic infection.3 All of these factors may also attribute to flare-ups of the 
condition; these include typical symptoms such as change in bowel movements, crampy 
abdominal pain, bloating, and excessive gas production. The nature of these symptoms clearly 
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illustrates how experiencing this condition would affect quality of daily living and emphasizes 
the need for effective treatment plans.  
 Unfortunately, there is currently no definitive treatment for irritable bowel syndrome. 
However, lifestyle modifications and medications have been classically trialed in the symptom 
management of IBS. Lifestyle modifications include, but are not limited to, following a low 
FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet, 
incorporating higher fiber content into the patient’s daily regimen, and avoiding symptom-
exacerbating agents (i.e., spicy foods). Pharmacologic interventions vary depending on the 
individual’s primary complaint; for IBS-D, medications such as loperamide have been used; for 
IBS-C, medications including laxatives, lubiprostone, and linaclotide have been used. In order to 
treat abdominal pain, medications such as antidepressants (selective serotonin reuptake 
inhibitors) and antispasmodics have been used.5  
 Having a diagnosis of irritable bowel syndrome can prove to have a negative impact on 
an individual’s daily life. In addition to physical symptoms, it often takes several months to settle 
on an appropriate management plan since the pathophysiology, and thus target mechanism, 
remains unknown. The effectiveness of the current treatment regimens depends on the individual 
patient, so not every patient may achieve relief or resolution of their symptoms. Ongoing 
research has proven that alterations in the gut microbiome may play a role in IBS. Probiotics are 
microorganisms such as live bacteria and yeast that provide health benefit and help restore gut 
flora. Thus, probiotic use has gained recent popularity in maintaining the gut microbiome and 
providing symptomatic relief of IBS.6  
OBJECTIVE 
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 The objective of this selective evidence-based medicine (EBM) review is to determine 
whether or not probiotics are effective in improving quality of life in adults with irritable bowel 
syndrome. 
METHODS  
The articles selected for this review were published in English and in peer-reviewed 
journals. Key words used to search for data included probiotics and irritable bowel syndrome. 
The articles were searched for using GoogleScholar and PubMed. When selecting appropriate 
journal articles for RCTs analyzing the effect of probiotic supplementation in adults with IBS on 
quality of life, certain criteria were identified. Inclusion criteria for these articles comprised of 
studies published after 2015 and RCTs. Exclusion criteria contained studies published before 
2015 and studies with patients aged 18 and under. Summary of statistics reported was the mean-
change from baseline. The studies selected were chosen based off of the relevance to the 
proposed clinical question and selected based on patient-oriented outcomes (POEMs). 
The studies evaluated in this review include three double-blind randomized controlled 
trials (RCTs). The population includes adults with IBS who meet the Rome III criteria for 
diagnosis. Study participants were randomized to either the intervention arm which received 
probiotic supplementation in pill form, or the control group which received a placebo pill. The 
primary outcome for all studies was the effect on quality of life in participants receiving 
probiotic supplementation versus those receiving placebo pills.    
OUTCOMES MEASURED 
 The outcomes measured in each study were based on POEMs that evaluated the 
effectiveness of probiotic supplementation and reported effect on quality of life. Each patient’s  
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Table 1. Demographics & Characteristics of Included Studies 
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quality of life was measured utilizing the IBS-QOL questionnaire score, which patients complete 
themselves, at 12 weeks, 60 days, and 16 weeks, respectively. The IBS-QOL questionnaire is 
based on eight domains: dysphoria, interference with activity, body image, heath-related worries, 
food avoidance, social reactions, sexual dysfunction, and relationships.3, 7, 8  
RESULTS 
Preston et al. studied 113 adults aged 18 and older with IBS symptoms utilizing a double-
blind randomized controlled trial design. Subjects in this study were recruited at three clinical 
sites based out of California. Each subject was randomized in a 2:1 ratio to receive either 
probiotic supplementation or placebo pills.3 The intervention group received 2 capsules with 
breakfast each day x 12 weeks, which included a formulation of a minimum of 50 x 109 CFU (L. 
acidophilus CL1285, L. casei LBC80R, and L. rhamnosus CLR2) with respective proportions of 
1-5%, 80-90%, and 5-15%, plus inert ingredients. The control group received 2 capsules with 
breakfast each day x 12 weeks, which was a placebo pill containing only inert ingredients.3 
Participants in this RCT were included if they met the Rome III criteria for IBS. The researchers 
excluded participants if they had other diagnosed GI disorders, prior abdominal surgery, life 
expectancy less than six months, if they were pregnant or breastfeeding, lactose intolerant, 
immunocompromised, diagnosed eating disorder, recent antibiotic use, allergic reaction to 
intervention, or current daily probiotic use. Eighty-five subjects completed the IBS-QOL 
questionnaire at conclusion of the study at 12 weeks. Overall, quality of life improvement was 
demonstrated for all domains in females and four domains in males. In order to measure the 
treatment effect, the mean change from baseline was calculated based on a 100-point scale for 
males and females; in the active intervention group, a mean change from baseline of 
24.0122.39 was recorded; in the placebo control group, a mean change from baseline of 
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18.4423.15 was recorded.3 Quality of life was improved by 30% in all adults included in the 
study, with a greater improvement of 65% in all adults with IBS-D predominant symptoms 
compared to the placebo group. In addition, females demonstrated an overall improvement of 
94% and 75% in females with IBS-D,  whereas males with IBS-D demonstrated improvement of 
38%.3 Overall improvement of males with IBS was not recorded. No measure of precision (i.e., 
confidence interval or p-value) was provided in this study.  
Table 2. Mean change from baseline for males and females at week 12 on IBS-QOL for Preston 
et al.3  
Group Subgroup Mean change from baseline (meanSD) Improvement % 
  Placebo Active  
Females 
and males 
All 18.4423.15 24.0122.39 30% 
IBS-D* 15.4413.10 25.4023.47 65% 
Females All 11.0318.86 21.4020.73 94% 
IBS-D* 12.7811.61 22.4024.78 75% 
Males IBS-D* 22.5516.70 31.0520.94 38% 
*IBS-D = diarrhea predominant 
Mezzasalma et al. followed a double-blind randomized controlled design which studied 
157 Caucasian participants with IBS-C from the ages 18 to 65 years old. The subjects were 
randomized in a 1:1 ratio for group F_1 (active) and F_3 (placebo) utilizing a computer-
generated randomization software.7 Both groups in this study received one capsule daily for 60 
days. The F_1 active intervention capsule consisted of the following: 5 x 109 CFU L. acidophilus 
(30 mg as lyophilized), 330 mg inulin, 5 mg silica, and 5 mg talc.  The placebo pill for group F_3 
was composed of 390 mg inulin, 5 mg silica, and 5 mg talc.7 All patients included met Rome III 
criteria, and were excluded based off of several parameters which can be found above in Table 1. 
In total, 150 of the participants completed the study and their results were measured using the 
IBS-QOL questionnaire at day 60 of the trial. This study utilized 12 items of the 34-item 
questionnaire as follows: (i) I am embarrassed by the smell caused by my bowel problems, (ii) I 
feel vulnerable to other illnesses because of my bowel problems, (iii) I feel fat because of my 
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bowel problems, (iv) I feel my life is less enjoyable because of my bowel problems, (v) I feel 
depressed about my bowel problems, (vi) I have to watch the amount of food I eat because of my 
bowel problems, (vii) because of my bowel problems, sexual activity is difficult for me, (viii) I 
feel angry that I have bowel problems, (ix) I feel I get less done because of my vowel problems, 
(x) my bowel problems limit what I can wear, (xi) I have to watch the kind of food I eat because 
of my bowel problems, (xii) I fear that I won’t be able to eat because of my bowel problems.7 
The scores were calculated based on a five-point scale: ranging from 1: not at all to 5: extremely. 
The results of this study showed an overall improvement in symptom severity in the active 
intervention group (F_1) compared to baseline and the placebo group (F_3), which yielded a 
statistically significant (p < 0.001) improvement in the HR-QOL questionnaire score. A mean 
change from baseline was calculated at different time points and compared at the end of the trial 
(day 60). Group F_1 was found to have a greater reduction in HR-QOL score.7 Table 3 displays 
these results, showing a mean change from baseline of 11.0  0.1, compared to group F_3 with 
an average reduction of 3.1  0.3.7 
Table 3. Mean change from baseline and statistical significance for adults at 60 days on IBS-
QOL for Mezzasalma et al.7 
 Mean change from baseline p-value 
Active (F_1) 11.0  0.1 <0.001* 
Placebo 
(F_3) 
3.1  0.3 <0.001* 
*p-value ≤ 0.05 is significant 
Ishaque et al. conducted a double-blind randomized controlled trial, which included 400 
adults aged 18-55 years with moderate-to-severe IBS-D symptoms. The study was executed at 
the BSMMU Gastroenterology department. Participants were randomized to either the active or 
placebo group utilizing a third-party online randomization generator.  The active intervention 
group received 2 capsules BID x 16 weeks (8 billion CFUs/day) of Bio-Kult®, either before or 
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with a meal. These capsules were made up of 14 different bacterial strains (2 billion 
CFUs/capsule), which included the following: Bacillus subtilis PXN 21, Bifidobacterium spp. (B. 
bifidum PXN, B. breve PXN 25, B. infantis PXN 27, B. longum PXN 30), Lactobacillus spp. (L. 
acidophilus PXN 35, L. delbrueckii spp. Bulgaricus PXN39, L. casei PXN 37, L. plantarum 
PXN 47, L. rhamnosus PXN 54, L.helveticus PXN 45, L. salivarius PXN 57, Lactococcus lactis 
PXN 63, and Streptococcus thermophilus PXN 66.8 The placebo group received two capsules 
BID x 16 weeks that were composed of microcrystalline cellulose in a vegetable capsule made of 
hydroxypropyl methycellulose. All patients included met Rome III criteria. Subjects were 
excluded if they used probiotic supplementation within the last 3 months, concurrent severe 
illness including cancer, uncontrolled diabetes mellitus, hepatic/renal/cardiac dysfunction, hyper-
/hypothyroidism, prior GI surgery, chronic bowel disorders such as inflammatory bowel disease 
(IBD), tuberculosis, diverticular disease, recent antibiotic use, pregnancy, and/or lactation.8 360 
of the 400 participants completed the trial (Bio-Kult® = 181, placebo = 179) and were evaluated 
using the IBS-QoL questionnaire monthly. Table 4 presents the results from the IBS-QoL 
questionnaire at follow-up visit one month following intervention cessation.8 It demonstrates a 
statistically significant (p<0.001) improvement in the mean change from baseline for the 
probiotic group (49.4  6.0) compared to the placebo group (31.0  3.8). It is important to note 
that, while the IBS-QoL scores at baseline are statistically significant (p<0.001), they vary 
considerably by a difference of 4.9  2.5 points (Bio-Kult® = 22.6   10.5, placebo = 27.5   
13.0). The study also found no statistical significance at follow-up with respect to age or gender. 
The IBS-QoL questionnaire evaluated eight dimensions such as follows: interference with 
activity, social reactions, relationships, food avoidance, dysphoria, sexual dysfunction, health-
related worries, and body image. The results yielded a consistently higher IBS-QoL score in the 
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probiotic intervention group when compared to the placebo group across all eight of these 
domains.8  
Table 4. Mean change from baseline and statistical significance for adults at 5th month on IBS-
QOL for Ishaque et al.8 
 Mean change from baseline p-value 
Bio-Kult® 49.4  6.0 <0.001* 
Placebo 31.0  3.8 <0.001* 
*p-value ≤ 0.05 is significant 
SAFETY AND TOLERABILITY 
 Overall, all three of the RCTs reported high tolerability in the probiotic and placebo 
groups. However, according to Preston et al. seven subjects (four of which received active 
intervention, and three received placebo) reported adverse effects from the respective 
medication. These adverse effects included dry mouth, increased perspiration, fatigue, and 
nausea. There was no evidence to definitively attribute the symptoms as adverse effects of the 
intervention.3 No serious adverse effects were reported in any of the three studies.  
DISCUSSION 
  Irritable bowel syndrome can be a discouraging condition to manage, both physically 
and mentally. Since the etiology of IBS is not well understood, no definitive treatment currently 
exists. In addition, because the prevalence is vast and increasing, it is important from many 
aspects of care to develop safe, affordable, and effective options to treat it. The three studies 
discussed above all illustrated an improvement in quality of life in those who suffer from IBS 
following probiotic use compared to placebo. Moreover, all of the studies, with the exception of 
Preston et al., produced a statistically significant response to the intervention. Although each of 
the studies looked at different subsets of IBS (i.e., IBS-D vs. IBS-C), the improvement in quality 
of life in the active intervention groups compared to placebo groups is consistent. Several other 
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studies and meta-analyses have been conducted to assess the role that probiotics play in 
management of IBS. While these three studies focused on the adult population with IBS, other 
research has shown improvement in IBS symptoms and quality of life when probiotics are used 
in children.9 Mezzasalma et al., specifically notes that because of the inconclusive knowledge in 
regards to IBS pathophyisiology, it is important for further studies to be developed to solidify 
evidence and efficacy of probiotic use for the treatment of IBS.7 With more studies supporting 
the use of probiotics for IBS management, this can provide a safe and cost effective option to 
decrease symptoms and improve quality of life. Although probiotics are not typically covered by 
insurance, they are reasonably affordable over-the-counter products.10 
 As with all studies, limitations exist amongst the RCTs included in this review. The 
above studies were limited by a small sample size. It is important to note the trial duration in 
comparison to the disease prognosis; the length of the studies in this review may be inadequate 
when considering that IBS is theoretically a lifelong disease.8 Additionally, because IBS is 
believed to have a psychological component, it is believed that the placebo effect may be 
overwhelming.3 This could pose a potential limitation on any IBS clinical trial. Preston et al., 
also noted differences in participant responses based on IBS subtype and gender, that were not 
accounted for in the data analysis.3 They also failed to provide a measurement of precision, such 
as a p-value, which restricts the ability to assess the significance of the results. Mezzasalma et 
al., found that the use of various types of probiotic strains and/or formulations may limit the 
generalizability of the study. Specific to Ishaque et al., it is important to consider the reliability 
of this data. As noted above, their intervention and placebo groups did not start at a similar 
baseline. This poses concern about whether the data from the study in its entirety is 
compromised.8  
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CONCLUSION 
 Based on the three randomized-controlled trials reviewed in this selective evidence-based 
medicine review, probiotic use is effective in improving quality of life in patients with IBS. Each 
of the above studies provided individual data that shows the use of probiotic supplementation in 
management of irritable bowel syndrome is promising. This finding has been further supported 
by other studies.7 However, larger studies need to be done in order to determine the exact 
efficacy of such intervention. Future research should try to maximize sample size and study 
duration, as well as consider different strains of probiotic bacteria and the different demographics 
and IBS subtypes in terms of managing symptoms.  
Regardless of limitations, the consistency in findings proves that probiotic use is on the 
right track to developing a more efficacious treatment strategy, which can hopefully improve 
both patient quality of life as well as national financial burden in regard to IBS costs.  
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